MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- AUROBINDO PHARMA LIMITED (pharmaceuticals)
- AUROBINDO PHARMA LIMITED Financial Data
Aurobindo Pharma Fact Sheet (AUBD)
LIVE on April 23rd: Has Covid impacted India's long-term growth potential?
Here is the latest financial fact sheet of Aurobindo Pharma. For more details, see the Aurobindo Pharma quarterly results and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
AUROBINDO PHARMA Price History
| % ch | % | 0.6 |
| No. of shares | m | 585.17 |
| % ch week | % | 9.1 |
| % ch 1-mth | % | 18.9 |
| % ch 12-mth | % | 83.7 |
| 52 week H/L | Rs | 1,023.1/525.1 |
AUROBINDO PHARMA Financials
| No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
|---|
| AUROBINDO PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 1,280 | 1,541 | 895 | 809 | 830 | |
| Low | Rs | 509 | 582 | 622 | 504 | 527 | |
| Sales per share (Unadj.) | Rs | 415.1 | 235.8 | 254.6 | 281.6 | 333.9 | |
| Earnings per share (Unadj.) | Rs | 54.0 | 34.6 | 39.3 | 41.4 | 40.4 | |
| Diluted earnings per share | Rs | 26.9 | 34.6 | 39.3 | 41.4 | 40.4 | |
| Cash flow per share (Unadj.) | Rs | 65.4 | 41.3 | 46.6 | 50.9 | 51.8 | |
| Dividends per share (Unadj.) | Rs | 4.50 | 2.50 | 2.50 | 2.50 | 2.50 | |
| Adj. dividends per share | Rs | 2.25 | 2.50 | 2.50 | 2.50 | 2.50 | |
| Dividend yield (eoy) | % | 0.5 | 0.2 | 0.3 | 0.4 | 0.4 | |
| Book value per share (Unadj.) | Rs | 184.5 | 124.5 | 160.0 | 199.4 | 237.1 | |
| Adj. book value per share | Rs | 92.0 | 124.5 | 160.2 | 199.6 | 237.4 | |
| Shares outstanding (eoy) | m | 291.98 | 585.17 | 585.88 | 585.88 | 585.91 | |
| Bonus/Rights/Conversions | - | PREF | ESOP | - | ESOP | ||
| Price / Sales ratio | x | 2.2 | 4.5 | 3.0 | 2.3 | 2.0 | |
| Avg P/E ratio | x | 16.6 | 30.7 | 19.3 | 15.9 | 16.8 | |
| P/CF ratio (eoy) | x | 13.7 | 25.7 | 16.3 | 12.9 | 13.1 | |
| Price / Book Value ratio | x | 4.8 | 8.5 | 4.7 | 3.3 | 2.9 | |
| Dividend payout | % | 8.3 | 7.2 | 6.4 | 6.0 | 6.2 | |
| Avg Mkt Cap | Rs m | 261,147 | 621,041 | 444,390 | 384,630 | 397,569 | |
| No. of employees | `000 | 11.6 | 13.3 | 14.0 | 17.3 | 17.9 | |
| Total wages/salary | Rs m | 13,023 | 15,426 | 17,678 | 21,308 | 25,849 | |
| Avg. sales/employee | Rs Th | 10,469.5 | 10,384.3 | 10,667.8 | 9,519.9 | 10,956.9 | |
| Avg. wages/employee | Rs Th | 1,124.9 | 1,160.9 | 1,264.3 | 1,229.4 | 1,447.7 | |
| Avg. net profit/employee | Rs Th | 1,361.1 | 1,522.9 | 1,645.8 | 1,397.9 | 1,324.3 | |
| AUROBINDO PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 121,205 | 137,986 | 149,157 | 164,998 | 195,636 | |
| Other income | Rs m | 967 | 2,038 | 1,159 | 1,020 | 1,553 | |
| Total revenues | Rs m | 122,172 | 140,024 | 150,316 | 166,018 | 197,189 | |
| Gross profit | Rs m | 25,636 | 31,882 | 34,343 | 37,718 | 39,519 | |
| Depreciation | Rs m | 3,326 | 3,924 | 4,276 | 5,580 | 6,680 | |
| Interest | Rs m | 1,599 | 2,568 | 667 | 777 | 2,626 | |
| Profit before tax | Rs m | 21,679 | 27,429 | 30,558 | 32,380 | 31,767 | |
| Minority Interest | Rs m | 45 | 15 | 50 | 31 | 27 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | -881 | |
| Tax | Rs m | 5,966 | 7,207 | 7,597 | 8,183 | 7,269 | |
| Profit after tax | Rs m | 15,758 | 20,236 | 23,012 | 24,229 | 23,645 | |
| Gross profit margin | % | 21.2 | 23.1 | 23.0 | 22.9 | 20.2 | |
| Effective tax rate | % | 27.5 | 26.3 | 24.9 | 25.3 | 22.9 | |
| Net profit margin | % | 13.0 | 14.7 | 15.4 | 14.7 | 12.1 | |
| AUROBINDO PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 83,794 | 102,944 | 92,062 | 121,878 | 153,645 | |
| Current liabilities | Rs m | 60,814 | 78,402 | 66,056 | 86,659 | 120,429 | |
| Net working cap to sales | % | 19.0 | 17.8 | 17.4 | 21.3 | 17.0 | |
| Current ratio | x | 1.4 | 1.3 | 1.4 | 1.4 | 1.3 | |
| Inventory Days | Days | 108 | 107 | 106 | 130 | 135 | |
| Debtors Days | Days | 107 | 122 | 68 | 68 | 64 | |
| Net fixed assets | Rs m | 39,218 | 50,278 | 62,919 | 83,345 | 103,909 | |
| Share capital | Rs m | 292 | 585 | 586 | 586 | 586 | |
| "Free" reserves | Rs m | 53,565 | 72,288 | 93,133 | 116,218 | 138,322 | |
| Net worth | Rs m | 53,857 | 72,873 | 93,719 | 116,804 | 138,908 | |
| Long term debt | Rs m | 13,111 | 7,428 | 1,814 | 4,512 | 1,800 | |
| Total assets | Rs m | 128,124 | 159,202 | 162,494 | 211,052 | 264,544 | |
| Interest coverage | x | 14.6 | 11.7 | 46.8 | 42.7 | 13.1 | |
| Debt to equity ratio | x | 0.2 | 0.1 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.9 | 0.9 | 0.9 | 0.8 | 0.7 | |
| Return on assets | % | 13.5 | 14.3 | 14.6 | 11.8 | 9.9 | |
| Return on equity | % | 29.3 | 27.8 | 24.6 | 20.7 | 17.0 | |
| Return on capital | % | 34.8 | 37.4 | 32.7 | 27.4 | 23.8 | |
| Exports to sales | % | 51.6 | 51.4 | 50.8 | 48.9 | 49.6 | |
| Imports to sales | % | 19.2 | 19.0 | 18.2 | 19.3 | 18.8 | |
| Exports (fob) | Rs m | 62,514 | 70,927 | 75,761 | 80,681 | 97,091 | |
| Imports (cif) | Rs m | 23,272 | 26,193 | 27,089 | 31,853 | 36,741 | |
| Fx inflow | Rs m | 62,613 | 71,015 | 75,838 | 80,727 | 97,316 | |
| Fx outflow | Rs m | 25,329 | 28,799 | 30,224 | 34,700 | 40,589 | |
| Net fx | Rs m | 37,284 | 42,216 | 45,613 | 46,027 | 56,727 | |
| AUROBINDO PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 12,368 | 14,198 | 32,786 | 19,545 | 16,220 | |
| From Investments | Rs m | -13,980 | -14,452 | -17,870 | -19,266 | -28,768 | |
| From Financial Activity | Rs m | 932 | 3,654 | -19,153 | 8,642 | 19,191 | |
| Net Cashflow | Rs m | -680 | 3,397 | -4,239 | 8,919 | 6,656 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: K. Ragunathan | COMP SEC: A. Mohan Rami Reddy | YEAR OF INC: 1986 | BSE CODE: 524804 | FV (Rs): 1 | DIV YIELD (%): 0.3 |
Read: AUROBINDO PHARMA 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: PIRAMAL ENTERPRISES NOVARTIS GLENMARK PHARMA SUN PHARMA NEULAND LABS
Compare AUROBINDO PHARMA With: PIRAMAL ENTERPRISES NOVARTIS GLENMARK PHARMA SUN PHARMA NEULAND LABS
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)
Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.
Views on news
AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)
Sep 15, 2020 | Updated on Sep 15, 2020For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)
Jun 5, 2020 | Updated on Jun 5, 2020For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Nov 6, 2019 | Updated on Nov 6, 2019Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA - ACTAVIS COMPARISON
COMPARE AUROBINDO PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.